Vertex Pharmaceuticals (VRTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX)

VRTX 433.85

-0.1%

3:24 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tommysdad who wrote (416)	5/16/2000 9:27:00 PM
From: Pseudo Biologist	Read Replies (2) of 1169

Thanks for your insights, as usual. BioCentury's story on the deal does mention JNK3 (c-jun-N-terminal kinase 3) as a target being in "preclinical development" and it states that "VRTX said (this target) is associated with neurological disease." Story also says that VRTX "had been working on several kinase subfamilies, including MAPK (p38 and VX-745 to be specific),JNK and ERK, each with a lead compound classes identified." On previous forays by Novartis's (NVS as of last week in the NYSE) predecessors into biotech, who can forget Sandoz's great gene therapy adventure(s)? (also mentioned in BioCentury). Let's see if we can get another trip down memory lane courtesy of biowa the historian -g- Last, it is interesting to compare this $800M biobuck deal with the $600M takeover of another kinase shop, SUGN by PNU/PHA. But maybe this should go to the valuation thread, or is it the new plateau? PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next